title: Anakinra: an effective treatment in the Schnitzler syndrome.
abstract: Schnitzler syndrome is a rare disease characterized by chronic urticarial eruption and a monoclonal gammapathy. The exact pathogenesis is still unclear and treatment remains a challenge. We report the case of a patient with a 2-year history of arthralgia, chronic urticaria rash and fever, not responding to different treatments including anti-histaminics, corticosteroids, colchicine and low dose methotrexate. A diagnostic of Schnitzler syndrome was suggested and treatment with anakinra, an interleukin-1 receptor antagonist, was started, leading to a rapid, complete and sustained remission of symptoms. Anakinra seems to constitute an efficient and safe therapeutic approach for this rare disease.
authors.affiliation: Service de médecine interne et maladies infectieuses, hôpital Saint-André, CHU de Bordeaux, Bordeaux cedex, France. marie-anne.vandenhende@chu-bordeaux.fr
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Vandenhende
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bentaberry
authors.forename: Philippe
authors.initials: P
authors.lastname: Morlat
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bonnet
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D012074:Remission Induction; D019873:Schnitzler Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1